37 results about "Bladder cancer cell" patented technology

This invention discloses a chimeric guide RNA integrating RNA interference and CRISPR-Cas13d and its applications. Utilizing the structural matching between shRNA and Cas13d crRNA, this invention embeds the complete Cas13d crRNA into the classic shRNA backbone, constructing a dual-pathway synergistic silencing chimeric guide RNA (SS-Rx). Experiments have demonstrated that SS-Rx possesses the dual activity of shRNA and CRISPR-Cas13d, exhibiting superior gene silencing efficiency compared to traditional RNA silencing tools, and can inhibit the proliferation, migration, and invasion of bladder cancer cells by suppressing tumor-related genes. This invention synergistically combines the advantages of RNA interference and CRISPR-Cas13d, providing an efficient and widely applicable framework for gene function research and RNA-targeted therapy, with significant economic benefits and broad application prospects.

The invention discloses a staurosporine glucoside derivative as well as a preparation method and application thereof, and belongs to the field of medicine synthesis. C3-NHCH3 of staurosporine is subjected to glycosylation modification, and the staurosporine glycoside derivative shown in the formula (I) is prepared. The glycoside derivative prepared by the invention has a better inhibition effect on human acute myeloid leukemia cells THP-1, human bladder cancer cells 5637, human colon cancer cells HCT-116, human pancreatic cancer cells PATU8988T and human liver cancer cells HuH-7, and the compound 5 also has an excellent inhibition effect on human gastric cancer cells MKN-45. A candidate compound is provided for development of drugs for bladder cancer, colon cancer, pancreatic cancer, liver cancer, stomach cancer or acute myeloid leukemia.

The application provides a chiral 2-position disubstituted indoline compound and a synthesis method and application thereof. The application uses a simple structure palladium catalyst and a chiral ligand as a catalyst system, and uses a newly designed allyl benzoxazinone as a raw material to perform a palladium catalyzed intramolecular asymmetric cyclization reaction, so that efficient asymmetric synthesis of the chiral 2-position disubstituted indoline compound is realized. The synthesis method is simple, the reaction condition is mild, the cost is low, and the efficiency is high; the raw material is cheap and easy to obtain, atom economy is good, and the substrate is widely applicable; the target product has high yield and high enantioselectivity; the chiral 2-position disubstituted indoline compound obtained by the application has excellent inhibition effect on bladder cancer cells, provides a scientific basis for developing a new candidate drug for treating bladder cancer, and has important significance for the treatment of bladder cancer.

The present application belongs to the field of biotechnology, and particularly relates to a new target for bladder cancer proliferation and metastasis progression research and application thereof, more particularly to LAMP5 as a marker for bladder cancer diagnosis and prognosis, and application of LAMP5 as a bladder cancer marker in preparation of a molecular targeted drug. The present application constructs a stable cell strain with LAMP5 expression knocked down in J82 and T24T cell strains, and functional experiments show that inhibition of LAMP5 expression can inhibit the proliferation and metastasis of bladder cancer cells in vitro and ectopic tumor in vivo. It can be seen that LAMP5 expression can be inhibited by using an LAMP5 expression inhibitor, thereby providing a potential therapeutic target for bladder cancer treatment.

The invention belongs to the technical field of biological medicines, and discloses a preparation method of a rhizoma smilacis glabrae exosome and application of the rhizoma smilacis glabrae exosome in bladder cancer. The preparation method comprises the following steps: cleaning, soaking and slicing a rhizoma smilacis glabrae medicinal material, adding a phosphate buffer solution, juicing in a juicer, and filtering to obtain crude juice; sequentially carrying out low-speed, medium-speed and ultra-high-speed centrifugal treatment through a differential ultra-speed centrifugal method to obtain a rhizoma smilacis glabrae precipitate; and resuspending by using a phosphate buffer solution, carrying out ultra-high-speed centrifugation and filtering by using a filter membrane to obtain the rhizoma smilacis glabrae exosome. System experiments prove that the exosome-like nano-particles extracted from rhizoma smilacis glabrae can be effectively taken by bladder cancer cells, can significantly inhibit the growth of bladder cancer in vivo and in vitro by inhibiting proliferation and invasion of cancer cells, inducing oxidative stress, apoptosis, cell cycle arrest and other mechanisms, and has no obvious toxic or side effect on normal tissues; good biological safety and clinical application prospects are realized.

The present invention relates to a composition for preventing or treating bladder cancer, in particular, to a composition for preventing or treating cancer, comprising a nucleic acid encoding a proenkephalin (PENK) protein, which is a cancer inhibitory protein that is inhibited by methylation in cancer cells, in particular, a PENK protein that is inhibited by methylation in bladder cancer cells. Thus, the composition inhibits proliferation of bladder cancer cells.

The invention discloses a bladder cancer cell and a method for constructing a mouse bladder cancer in-situ model by using the bladder cancer cell. The preservation number of the bladder cancer cells is CCTCC (China Center For Type Culture Collection) NO: C2025187. The migration and invasion abilities of bladder cancer cells provided by the invention are higher than those of parent cells, when the bladder cancer cells are used for constructing a mouse bladder cancer in-situ model, the tumor growth speed, proliferation ability and modeling rate are higher than those of the parent cells, and an efficient animal model platform is provided for bladder cancer related research.

The application discloses application of NDUFB4 as a target point in preparation of a drug for treating bladder cancer. Single cell analysis results show that NDUFB4 is highly enriched in bladder cancer epithelial cells, and can be used as a key coordinator to participate in the regulation of multiple carcinogenic signal pathways. Through shRNA-mediated gene silencing and CRISPR / Cas9-mediated gene knockout experiments, it is found that NDUFB4 deletion can significantly inhibit the proliferation, migration and invasion ability of bladder cancer cells, and cause a serious bioenergy crisis, and activate the endogenous apoptosis pathway. In a subcutaneous xenotransplant tumor model, it is further verified that NDUFB4 silencing can significantly inhibit tumor growth. The application discloses that NDUFB4 is a key coordinator between mitochondrial high-functionality and carcinogenic signal pathways, and it is suggested that NDUFB4 can become a potential target for bladder cancer treatment.

The invention discloses a new application of rhizoma paridis total saponins in preparation of a medicine for enhancing bladder cancer cell ferroptosis and apoptosis sensitivity, the rhizoma paridis total saponins are combined with a GPX4 inhibitor JKE for use, and experiments show that the rhizoma paridis total saponins can enhance the sensitivity of bladder cancer cells (UM-UC-3, T24CDDP) to the JKE, and cooperate with the JKE to reduce the median inhibitory concentration of the bladder cancer cells, so that the bladder cancer cell ferroptosis and apoptosis sensitivity can be enhanced, and the bladder cancer cell ferroptosis and apoptosis sensitivity can be enhanced. The paris polyphylla total saponins are combined with JKE, the synergistic effect is dose-dependent within a certain range, and in the aspect of ferroptosis, when the paris polyphylla total saponins and JKE are used in a combined manner, C11-BODIPY detection finds that cells can be more effectively induced to generate lipid peroxidation, and ferroptosis is promoted. An apoptosis detection result shows that the rhizoma paridis total saponins can enhance the effect of inducing bladder cancer cell apoptosis by JKE, and flow cytometry detection shows that the apoptosis rate is remarkably increased when the rhizoma paridis total saponins are combined for use; the combined application of the rhizoma paridis total saponins and the JKE provides a new effective strategy for bladder cancer treatment.

The invention provides a sugar nucleic acid dual-targeting radioactive molecular probe for targeted therapy of bladder cancer as well as a preparation method and application of the sugar nucleic acid dual-targeting radioactive molecular probe, and belongs to the technical field of biological medicines. The probe is composed of an Sgc8 aptamer for recognizing bladder cancer cell PTK7 protein, three nitrine mannose molecules of a targeted M2 type macrophage CD206 receptor and a DOTA structure for chelating 177Lu, and precise assembly is achieved through a click chemical reaction and complementary base pairing. The probe has dual targeting ability, can act on bladder cancer cells and M2 type macrophages in a tumor microenvironment at the same time, significantly prolongs the retention time (gt, 48 hours) in the bladder, induces immune activation while killing tumor cells, and realizes the synergistic effect of radiotherapy and immunotherapy. The problems that an existing bladder cancer treatment probe is insufficient in targeting, poor in stability and limited in treatment effect are solved, a new strategy is provided for precise treatment of bladder cancer, and the bladder cancer probe has good clinical transformation value.

The application discloses a kind of 1,5-diaryl-1,2,4-triazole compounds or pharmaceutically acceptable salt represented by structural formula I, II or pharmaceutical composition containing such compounds.The application also discloses the application of the compound or pharmaceutically acceptable salt in the preparation of drugs for treating various malignant tumors and related diseases of tumor metastasis.The compound represented by formula I, II of the application can inhibit the proliferation, invasion and infiltration of tumor cells such as gastric cancer cells, breast cancer cells, prostate cancer cells, colon cancer cells, liver cancer cells, non-small cell lung cancer cells and bladder cancer cells in a concentration gradient-dependent manner, has the characteristics of high efficiency and low toxicity, and has a wide application prospect in the biological medicine industry.

The application discloses a bladder cancer cell segmentation method and device based on urine sediment microscopy and a storage medium; the method comprises the following steps: taking a urine sediment microscopy image as an input image, inputting the input image into a detection model, marking a high-suspected cancer cell area in the input image through the detection model, and generating a boundary box; segmenting the high-suspected cancer cell area in the boundary box through a segmentation model, obtaining a mask of each cancer cell, deleting the corresponding boundary box if the mask is empty or the area ratio is lower than a preset threshold, mapping the effective mask back to the input image, merging all the effective masks, and generating a segmentation result of the cancer cells. The detection model can effectively reduce the processing range of the segmentation model, avoid the waste of computing resources caused by full-image search, and improve the processing speed. The segmentation model can automatically filter out false detection or invalid areas, and ensure the accuracy and reliability of the segmentation result.

The invention discloses a new application of tripterine, namely application of the tripterine in preparation of bladder cancer resisting drugs, in-vitro cell experiments prove that the tripterine shows remarkable proliferation inhibition activity on various bladder cancer cell strains including cell strains UM-UC-3, TCCSUP and T24 and a cis-platinum drug-resistant strain T24CDDP, the median inhibitory concentration (IC50) of the tripterine is 0.2688-0.5870 mu M, and the tripterine shows remarkable proliferation inhibition activity on various bladder cancer cell strains including cell strains UM-UC-3, TCCSUP and T24 and a cis-platinum drug-resistant strain T24CDDP. The further mechanism research shows that the tripterine can regulate and control the cell cycle by down-regulating the expression levels of CDK1 and CDC5L proteins in bladder cancer cells and up-regulating the expression of phosphorylated p53 (p-p53) proteins at the same time, thereby playing a role in resisting bladder cancer; the invention provides a new effective candidate drug for clinical treatment of bladder cancer, especially cis-platinum resistant bladder cancer, and has important clinical application value.

The invention discloses an application of cypress hydrolat in preparation of antitumor drugs. The tumors comprise liver cancer, gastric cancer, lung cancer, cervical cancer, prostatic cancer and / or bladder cancer. Experiments show that the cypress hydrolat has an obvious inhibition effect on proliferation of gastric cancer SGC-7901, lung cancer A549, cervical cancer Hela, liver cancer Bel-7402 and HepG2, prostatic cancer PC-3 and bladder cancer EJ cells, can inhibit migration of two human liver cancer Bel-7402 and HepG2 cells, can prolong life of ascites tumor mice and inhibit growth of tumors, and can be used for preparing the cypress hydrolat. The cypress hydrolat has antineoplastic activity and antineoplastic effect, has the patent medicine potential of preparing medicine preparations for preventing or treating tumors, and can be used for developing and preparing antineoplastic medicines. The invention provides a new drug source for treating and curing liver cancer, gastric cancer, lung cancer, cervical cancer, prostatic cancer and bladder cancer, and provides a certain experimental basis for clinical application of the cypress hydrolat and development of new antitumor drugs.

The invention discloses an FGFR3 (Fibroblast Growth Factor Receptor 3) targeting antibody coupling medicine as well as a preparation method and application thereof. The antibody coupling medicine LZU-WZLYCS01 is formed by coupling an FGFR3 (Fibroblast Growth Factor Receptor 3) antibody with a cytotoxic load 7-ethyl-9-fluorocamptothecin through a cleavable linker GGFG (Growth Growth Factor Growth). The antibody coupling medicine disclosed by the invention shows remarkable cell growth inhibition activity on bladder cancer cells (such as T24 and UMUC-3), IC50 values within 72 hours are 0.005 mu M and 0.009 mu M respectively, and the antibody coupling medicine shows accurate targeting capability based on an FGFR3 target spot. In a bladder cancer organ model, a cell line-derived xenotransplantation tumor (CDX) model and a patient-derived xenotransplantation tumor (PDX) model, the LZU-WZLYCS01 can be used for effectively inhibiting tumor growth and has good safety. Therefore, the antibody coupling medicine is a candidate medicine with great potential for targeted therapy of bladder cancer.

This invention discloses the application of TRIM21-related biopharmaceuticals in the preparation of YME1L1-related products. It reveals the interaction between TRIM21 and YME1L1 and its key regulatory mechanism in the development and progression of bladder cancer. Studies show that TRIM21 specifically binds to the YME1L1 protein through its SPRY domain, mediating K63-linked ubiquitination modification of YME1L1 and thus promoting its protein degradation. Functional experiments confirm that TRIM21 inhibits the proliferation, migration, invasion, and mitochondrial function of bladder cancer cells and induces apoptosis by downregulating YME1L1 protein levels. This invention elucidates for the first time the tumor-suppressive mechanism of the TRIM21-YME1L1 signaling axis in bladder cancer, providing a new molecular marker for the diagnosis and prognostic assessment of bladder cancer, and offering a theoretical basis and intervention strategy for developing anti-tumor drugs targeting the TRIM21 / YME1L1 pathway.

The present application relates to a kind of preparation of new indole camptothecin derivatives and its use in antitumor, the structure of the compound general formula is shown as follows.In vitro cytotoxic activity screening results show that new indole camptothecin derivatives have broad-spectrum antitumor activity, to human hepatoma cell (HepG2), human non-small cell lung cancer cell (A549), human colon cancer cell (SW480), human intrahepatic cholangiocarcinoma cell (RBE), human breast cancer cell (MCF-7), human pancreatic cancer cell (BxPC3), human bladder cancer cell (T24), human bladder cancer cell (umuc3) show strong inhibitory activity. Among them, the antitumor activity of compound D-18 is most outstanding, and shows strong inhibition to the 8 tumor cell lines measured, IC 50 The range is 0.2585-10.69 μM, significantly better than the control drug irinotecan, and comparable to topotecan activity. Therefore, indole camptothecin derivatives are expected to be developed into a new antitumor drug.

The invention discloses application of jujuboside A in treatment of bladder cancer. Cell experiments prove that jujuboside A can reduce the activity of bladder cancer cells and induce apoptosis of the bladder cancer cells, and can inhibit expression of ATP1A2 in the bladder cancer cells and mitochondrial energy metabolism. The application provides a brand new thought for research and development of bladder cancer treatment medicines, and has a wide application prospect.

The invention provides application of amentotaxus biflavone in preparation of a medicine for treating bladder cancer, and provides application of amentotaxus biflavone in preparation of a medicine for treating bladder cancer, which has the advantages that by increasing the concentration of amentotaxus biflavone, the number of bladder cancer cells is gradually reduced, the cells are shrunk, nuclear shrinkage of different degrees is caused, the activity, proliferation, invasion and migration of bladder cancer T24 cells and bladder cancer 5637 cells are inhibited, and the bladder cancer is treated. The PI3K / AKT / NF-kappa B pathway promotes the expression of a pro-apoptosis gene Bax in bladder cancer cells, inhibits the expression of an apoptosis inhibitor gene Bcl-2, inhibits the proliferation of the bladder cancer cells by inducing G1 phase retardation of the bladder cancer cells, induces and reduces the expression of PI3K, AKT and NF-kappa B proteins in cell nucleuses through the PI3K / AKT / NF-kappa B pathway, and induces the apoptosis of the bladder cancer cells. The invention belongs to the field of medicine.

The invention discloses application of brazilin in preparation of a medicine for inducing endoplasmic reticulum stress of bladder cancer cells. Experiments provided by the invention prove that brazilin can inhibit the progress of bladder cancer in vitro and in vivo, and reduce the Khib level of protein enriched in a protein folding pathway, so that endoplasmic reticulum stress is triggered, a PERK-eIF2alpha-ATF4-CHOP axis is activated, and CHOP-mediated cell apoptosis is driven. According to the application disclosed by the invention, the anti-tumor effect of the brazilin is researched by associating with Khib proteome remodeling and endoplasmic reticulum stress-induced apoptosis for the first time, and the research shows that the brazilin can be used for preparing medicines for treating bladder cancer or assisting in postoperative treatment.

This invention discloses a VH032-modified phthalocyanine, its preparation method, and its applications. A chemical synthesis method involving amino and carboxyl coupling is employed. The photosensitizer ZnPc and the Von Hippel-Lindau (VHL) ligand VH032 are linked using either no linker or an alkyl or PEG chain as a linker to construct the VH032-modified phthalocyanine. This drug can degrade VHL after light irradiation and, combined with photodynamic therapy (PDT), efficiently kill tumor cells, achieving a phototoxicity index (PI) of 36397. Utilizing the more active regulation of Cyclin Dependent Kinase 2 / 4 (CDK2 / 4) by VHL in bladder cancer tumor tissue, after light irradiation, this compound exhibits a selectivity index (SI) of 749 for killing bladder cancer cells compared to normal cells, achieving selective killing of tumor cells under light conditions and effectively avoiding the risk of damage to adjacent normal tissues during treatment.

The application provides a method for evaluating smoker index and application thereof in bladder cancer treatment and evaluation. The application has carried out in-depth research on the pathogenesis and development mechanism of bladder cancer, found that smoking is a risk factor highly correlated with bladder cancer, and constructed a quantifiable model-smoker index which can be used for system evaluation of the smoking state of patients, so that the prognosis and survival state of bladder cancer patients can be more accurately predicted and evaluated through analysis of the expression level of specific markers in the body of the subjects. The application clarifies the correlation between CGB5 and bladder cancer, and can effectively inhibit the proliferation, migration and other activities of bladder cancer cells by inhibiting the expression of CGB5. The application provides a new drug treatment target for human to conquer bladder cancer, thereby providing a new direction for subsequent drug research and development, clinical treatment and the like, and has very high social value and market application prospect.

The invention discloses application of pentadecanoic acid in preparation of a medicine for preventing or treating bladder cancer, and belongs to the technical field of treatment and prevention of bladder cancer. The invention relates to application of pentadecanoic acid in preparation of a medicine for preventing or treating bladder cancer. Wherein the pentadecanoic acid is found to have excellent anti-tumor activity for the first time and particularly has a remarkable inhibiting effect on bladder cancer, and the research finds that the pentadecanoic acid can remarkably inhibit invasion, migration and multiplication capacity of bladder cancer cells and inhibit growth of BBN-induced mouse bladder cancer and has potential for preventing or treating bladder cancer; the invention provides a theoretical basis for researching the treatment strategy of the bladder cancer, and provides an entry point for preparing a new medicine for preventing or treating the bladder cancer.

The invention discloses a novel application of polyphyllin VII in preparation of a medicine for enhancing ferroptosis sensitivity of human bladder cancer cells and liver cancer cells, the polyphyllin VII is combined with a GPX4 inhibitor for use, and experiments show that the polyphyllin VII can enhance the sensitivity of the bladder cancer cells to JKE and can reduce the median inhibitory concentration of the bladder cancer cells in cooperation with the JKE; when the polyphyllin VII is respectively combined with the GPX4 inhibitor JKE, ML210, RSL3 or ML162 for use, the polyphyllin VII has the effect of synergistically inhibiting the activity of liver cancer cells; the synergistic effect is dose-dependent within a certain range; the result and discovery in bladder cancer cells verify each other, and the result shows that the PPVII can be used as a broad-spectrum ferroptosis sensitizer, is not limited to bladder cancer, and also shows huge application potential in treatment of liver cancer, and the invention provides a brand-new drug combination strategy for overcoming tumor drug resistance.

The invention discloses tsRNA (transfer ribonucleic acid) and application thereof. The nucleotide sequence of the tsRNA is as shown in SEQ ID NO: 1. The novel tsRNA molecule provided by the invention can be accurately used for diagnosing the bladder cancer, and meanwhile, after the tRF3-16-AlaAGC-1 is knocked down, proliferation and migration of bladder cancer cells can be inhibited, the activity of the bladder cancer cells can be reduced, the liver metastasis rate of the bladder cancer cells can be reduced, and a novel powerful molecular biological tool is provided for treatment of the bladder cancer. The method has profound clinical significance and important popularization and application prospects.

The invention discloses an antibody coupling medicine LZU-WZLY-WYR02 as well as a preparation method and application thereof, and belongs to the technical field of medicines. The drug is composed of three parts: a humanized monoclonal antibody targeting FGFR3, a linker GGFG capable of being subjected to enzyme digestion, and cytotoxin 7-ethyl-10-fluorocamptothecin. The linker GGFG is connected with toxin through a carbonate bond, and is coupled to a lysine site of an antibody through an amido bond to form an ADC drug which is clear in structure, uniform in DAR and good in stability. The drug shows excellent tumor targeting and antitumor activity in FGFR3 high-expression bladder cancer cell lines (such as T24 and UMUC-3) and animal models (CDX and PDX), has low toxic and side effects, and has important clinical application value.

The invention relates to the technical field of bladder cancer treatment, and particularly discloses a method for inducing necrotic apoptosis of bladder cancer cells by inhibiting ADM up-regulation of STAT1, and the method comprises the following steps: resuscitating a cell cryopreservation tube filled with a human bladder cancer cell strain T24, and then adding the cell cryopreservation tube into a complete culture medium for cell culture; when the growth density of the human bladder cancer cells reaches 80%, pancreatin is added for digestion to prepare a cell suspension, then centrifugation is performed, a supernatant is discarded, and subculture is performed after resuspension; the method comprises the following steps: preparing cells in subculture into a cell suspension, inoculating the cell suspension into a 6-well plate for culture, then discarding a culture medium, adding a 1640 culture medium, adding ADM-siRNA and LipofectamineTM3000 for transfection, collecting the cells, and detecting the apoptosis condition. According to the invention, ADM-SiRNA is transfected in bladder cancer cells to knock down the expression of ADM and up-regulate the expression of STAT1, so that an STAT1-mediated RIPK1 / RIPK3 / MLKL signal channel is activated, and bladder cancer cell apoptosis is promoted, so that the invention provides an important theoretical basis and practical guidance for developing accurate and efficient anti-tumor therapy.

This invention discloses an engineered extracellular vesicle system for constructing an in situ cell factory, its preparation method, and its applications. Specifically, it involves the in situ production of drug molecules with cytotoxic effects within bladder cancer cells under urea-mediated conditions, enabling the application of a urea-mediated targeted in situ killing system for the precision treatment of bladder cancer. Leveraging the unique microenvironment of a high urea concentration of 300 mmol / L within the bladder where bladder cancer lesions are located, an engineered extracellular vesicle system, P@EV, is constructed. VR+U Through the synergistic effect of RGD tumor targeting, VSVG pH-responsive membrane fusion and UTB urea transport function, PGA-1 can be efficiently delivered into bladder cancer cells, promoting intracellular urea accumulation and in situ generation of the cytotoxic product Compound-1.

This invention discloses the application of CALD1 protein in the preparation of drugs for treating bladder cancer, belonging to the field of biomedical technology. The application of CALD1 protein in the preparation of drugs for treating bladder cancer: This invention, through the construction of drug-resistant cell lines using in vivo animal models and combined with clinical sample analysis, first discovered that CALD1 is highly expressed in cisplatin-resistant bladder cancer cells and is associated with poor patient prognosis, demonstrating that CALD1 is a potential novel target for treating cisplatin resistance in bladder cancer, which is beneficial for further research on the mechanism of tumor chemotherapy resistance caused by abnormal activation of CALD1.

The invention relates to the technical field of biological medicines, and provides application of siRNA (small interfering Ribonucleic Acid) targeting IFI44 in preparation of medicines for inhibiting malignant progression of bladder cancer. The siRNA is selected from siRNA (Ribonucleic Acid) 1 or siRNA 2; the siRNA1 comprises a positive-sense strand of which the nucleotide sequence is as shown in SEQ ID NO.1 and an antisense strand of which the nucleotide sequence is as shown in SEQ ID NO.2; the siRNA2 comprises a positive-sense strand of which the nucleotide sequence is as shown in SEQ ID NO.3 and an antisense strand of which the nucleotide sequence is as shown in SEQ ID NO.4. The siRNA targeting IFI44 is applied to preparation of drugs for inhibiting the malignant progression of bladder cancer, and proliferation and migration of bladder cancer cells are inhibited and apoptosis of the bladder cancer cells is promoted by reducing the expression level of IFI44, so that the malignant progression of the bladder cancer is inhibited.